Zealand Pharma A/S

ZEAL · Nasdaq Copenhagen · Healthcare

265.90DKK +4.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −41.8%

Performance

1 month

−14.4%

1 year

−41.8%

3 years, per year

−5.0%

5 years, per year

+5.6%

Largest fall, 3 years

−75.4%

Below the peak now

−72.1%

Volatility, 1 year

66.3%

Return with dividends reinvested.

Key figures

P/E

5.9

P/B

1.0

Dividend yield

0.0%

Return on equity

+17.5%

Net margin

+68.4%

Market value

2.8 bn USD

Quality, value and trend

Where Zealand Pharma stands against every Nordic stock today. 100 is best.

Quality99

Profitability and a sound balance sheet over time. Better than 99% of Nordic stocks.

Value76

The price measured against earnings, assets and cash flow. Better than 76% of Nordic stocks.

Trend18

The price development over the past year. Better than 18% of Nordic stocks.

Combined78

Quality, value and trend together. Better than 78% of Nordic stocks.

About Zealand Pharma

Zealand Pharma A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 580 employees.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis